Crinetics' Once-Daily Oral Paltusotine Achieved the Primary
83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an...
United States Corey Davis Chas Schultz Ir Corporate Communications Crinetics Pharmaceuticals Securities Exchange
Source: globenewswire.com